Cullinan Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share amounts)
| 2025 | 2024 | |
|---|---|---|
| Operating expenses: | ||
| Research and development | $187,402 | $142,903 |
| General and administrative | 54,246 | 54,016 |
| Total operating expenses | 241,648 | 196,919 |
| Loss from operations | (241,648) | (196,919) |
| Other income (expense): | ||
| Interest income | 22,212 | 29,660 |
| Other income (expense), net | (443) | (199) |
| Net loss before income taxes | (219,879) | (167,458) |
| Income tax expense | — | 117 |
| Net loss | (219,879) | (167,575) |
| Net loss attributable to noncontrolling interests | — | (192) |
| Net loss attributable to Cullinan | $(219,879) | $(167,383) |
| Comprehensive income (loss): | ||
| Net loss | $(219,879) | $(167,575) |
| Unrealized gain (loss) on investments | 1,153 | (4) |
| Comprehensive loss | (218,726) | (167,579) |
| Comprehensive loss attributable to noncontrolling interests | — | (192) |
| Comprehensive loss attributable to Cullinan | $(218,726) | $(167,387) |
| Basic and diluted net loss per share attributable to Cullinan: | ||
| Common stock | $(3.36) | $(2.78) |
| Preferred stock | $(33.57) | $(27.78) |
| Weighted-average shares used in computing basic and diluted net loss per share attributable to Cullinan: | ||
| Common stock | 59,050 | 53,771 |
| Preferred stock | 645 | 648 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.